McGhie D, Kerfoot P, Talbot D J
J Int Med Res. 1986;14(5):254-60. doi: 10.1177/030006058601400505.
Two treatments, pivmecillinam 200 mg plus pivampicillin 250 mg (Miraxid) given twice-daily and amoxycillin 250 mg plus clavulanic acid 125 mg (Augmentin) given three times daily were compared in two parallel groups of 388 general practice patients with acute bronchitis or acute exacerbations of chronic bronchitis. Patients with acute bronchitis (140 on Miraxid, 144 on Augmentin) received a 7-day course of treatment and those with acute exacerbations of chronic bronchitis (55 on Miraxid, 49 on Augmentin) a 10-day course of treatment. Both treatments were equally effective, with 99 (71%) patients with acute bronchitis being successfully treated with Miraxid and 107 (74%) with Augmentin. In acute exacerbations of chronic bronchitis, Miraxid was successful in 29 (53%) patients and Augmentin in 24 (49%) patients. Side-effects were reported by 26 (12%) of patients in both treatment groups. This single blind multicentre general practice study comparing twice-daily Miraxid with 3 times daily Augmentin demonstrated that both treatments were equally effective clinically and equally well tolerated.
在两组各有388名患有急性支气管炎或慢性支气管炎急性加重的全科门诊患者中，对两种治疗方案进行了比较。一种方案是每天两次服用200毫克匹美西林和250毫克匹氨西林（Miraxid），另一种方案是每天三次服用250毫克阿莫西林和125毫克克拉维酸（阿莫西林克拉维酸钾，Augmentin）。患有急性支气管炎的患者（140人服用Miraxid，144人服用阿莫西林克拉维酸钾）接受为期7天的疗程治疗，而患有慢性支气管炎急性加重的患者（55人服用Miraxid，49人服用阿莫西林克拉维酸钾）接受为期10天的疗程治疗。两种治疗方案效果相当，服用Miraxid的140例急性支气管炎患者中有99例（71%）得到成功治疗，服用阿莫西林克拉维酸钾的144例中有107例（74%）。在慢性支气管炎急性加重患者中，服用Miraxid的55例中有29例（53%）治疗成功，服用阿莫西林克拉维酸钾的49例中有24例（49%）。两个治疗组中均有26例（12%）患者报告有副作用。这项单盲多中心全科门诊研究比较了每日两次服用Miraxid和每日三次服用阿莫西林克拉维酸钾的疗效，结果表明两种治疗方案在临床疗效和耐受性方面均相当。
